Beijing Sait Mingqiang Pharmaceutical Technology

Beijing Sait Mingqiang Pharmaceutical Technology is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative small molecule drugs for oncology and metabolic disorders. Founded in 2014 by Dr. Guo Ming, the company focuses on the DNA damage response (DDR) pathway, with a pipeline featuring inhibitors of PARP, WEE1, and ATR. Its lead candidate, ST-1891, is a potent PARP1/2 inhibitor currently undergoing clinical evaluation for various solid tumors. The company utilizes its internal research capabilities to advance first-in-class and best-in-class therapies aimed at addressing significant unmet medical needs. Sait Mingqiang has secured backing from prominent investors like Qiming Venture Partners to support its clinical programs and expansion. The leadership team brings extensive experience from global pharmaceutical giants, positioning the company to bridge the gap between innovative research and clinical application.